The SPARK-CVD China survey highlights a gap between awareness and practice in systemic inflammation (SI) testing in ASCVD and CKD. 73% of physicians recognized SI as a key driver of CV, only 35% discussed it with patients! 🔗doi.org/10.1016/j.athplu.202…

Beyond lipid regulation, VSMC-derived PCSK9 drives vascular inflammation, phenotypic switching, and plaque progression. PCSK9 inhibition may stabilize plaques beyond LDL lowering. 🔗doi.org/10.1016/j.athplu.202… @society_eas

Do you remember when you joined X? I do! #MyXAnniversary

Langslet et al. explored retinal arteriolosclerosis in patients with genetically verified familial hypercholesterolemia. Despite lifelong LDL-C exposure, FH was not associated with increased retinal arteriolosclerosis vs controls. 🔗doi.org/10.1016/j.athplu.202… #FH #Atherosclerosis

📢 Call for Papers | Atherosclerosis Plus How do sex differences influence ASCVD biology, clinical manifestations and response to therapy? Contribute to Special Issue: Gender difference in ASCVD and therapeutic treatments of dyslipidemia sciencedirect.com/journal/at…

Great news for Atherosclerosis Plus! Our journal has received a CiteScore 2025 of 3.7. Thank you to all authors, reviewers, readers, and editors for contributing to the journal’s growing impact. #Atherosclerosis #CardiovascularResearch #OpenAccess #CiteScore

How does time since last meal affect lipoprotein and inflammatory biomarkers? In healthy young adults, Jensen et al. found that six VLDL particle subclasses rose 11–429% within 2–4h after breakfast, with IL-6 increasing ~325% at 10h. 🔗 doi.org/10.1016/j.athplu.202… @society_eas

From the archive: HDL-replacement therapy remains a fascinating translational field. This review discusses traditional and emerging clinical applications of HDL-based approaches, from lipid biology to therapeutic perspectives. 🔗doi.org/10.1016/j.athplu.202…

Inflammation and metabolic dysfunction are key drivers of atherosclerosis. A new study in Ath Plus shows that the C-reactive protein–triglyceride–glucose index is independently associated with peripheral artery disease in U.S. adults. 🔗doi.org/10.1016/j.athplu.202… @society_eas

Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD). FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood. 🚨 Early diagnosis and treatment can dramatically improve — and even normalize — life expectancy. Yet, fewer than 10% of affected children in Europe are currently identified. The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights: ✔️ Improved diagnostic criteria ✔️ Earlier treatment initiation — sometimes from age 6 ✔️ Lower LDL-C treatment targets ✔️ New lipid-lowering therapies ✔️ Updated treatment algorithms ✔️ Better transition from paediatric to adult care The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age. Read the full publication: eas.to/consensus-fhinchildre… To the press release: eas.to/consensus-fhinchildre… To the key messages: eas-society.org/publications…

Can environmental pollution shape cardiovascular risk through autoimmunity? This new geospatial study shows that hotspots of anti-apoA-I autoantibodies overlap with areas of higher air/soil pollution and lower life expectancy in Geneva. 🔗doi.org/10.1016/j.athplu.202… @society_eas

New Expert Consensus on Lipoprotein(a) in the Gulf Countries highlights the urgent need to integrate #Lp(a) into cardiovascular risk assessment! 🔗doi.org/10.1016/j.athplu.202… @society_eas

Even among adults with normal glucose and TG levels, a higher #TyG index is linked to systemic inflammation and arterial stiffness — especially in women. #TyG as an early marker of cardiometabolic risk. doi.org/10.1016/j.athplu.202… @society_eas

Same condition, different risks. In hypercholesterolemia, Lp(a) is a key driver of CAD in women—but not in men, where smoking and hypertension prevail. 🔗doi.org/10.1016/j.athplu.202… @society_eas

CNN3 emerges as a key player in atherosclerosis: it is increased in plaques and in patients’ blood, and promotes VSMC proliferation and migration. Circulating CNN3 also shows promise as a diagnostic biomarker 🔗doi.org/10.1016/j.athplu.202…

PCSK9 inhibition does not alter monocyte subset distribution in high-risk patients, but reshapes monocyte–lipoprotein interactions. An Lp(a)–intermediate monocyte link emerges, while KIV-2 repeats appear to drive inflammation more than Lp(a) levels. doi.org/10.1016/j.athplu.202…

Real-world evidence confirms bempedoic acid delivers ≥20% LDL-C reduction, consistent with RCTs. Effective both with statins and in statin-intolerant patients. No new safety signals observed. doi.org/10.1016/j.athplu.202… @society_eas

Calciprotein particles (CPPs), formed during calcium–phosphate overload, impair autophagic flux in vascular cells via lysosomal dysfunction. A mechanistic link between chronic mineral stress and vascular dysfunction doi.org/10.1016/j.athplu.202… @society_eas

HIV is no longer just a chronic infection—it’s a cardiovascular risk factor. This population-based study in Uganda finds higher arterial stiffness and ~2x increased odds among PLWH. Time to integrate CVD screening into HIV care. doi.org/10.1016/j.athplu.202…

Is there a link between non-steroidal anti-inflammatory drugs and cardiovascular risk in patients with inflammatory arthritis? 🔗doi.org/10.1016/j.athplu.202… @society_eas